Compare Stocks: DAWN, PRAX, PCVX, and CYTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$67.74 -1.5%	$76.51	$47.22 ▼ $88.31	$8.43B	0.36	2.13 million shs	1.01 million shs
DAWN Day One Biopharmaceuticals	$21.53	$19.41	$5.64 ▼ $21.53	$2.22B	-1.74	1.52 million shs	2.99 million shs
PCVX Vaxcyte	$59.09 +1.7%	$58.47	$31.51 ▼ $65.00	$8.79B	1.22	1.38 million shs	788,789 shs
PRAX Praxis Precision Medicines	$298.63 -0.1%	$339.20	$41.78 ▼ $392.70	$8.34B	2.76	458,070 shs	436,678 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-6.76%	-10.49%	-13.12%	+41.35%
DAWN Day One Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+216.15%
PCVX Vaxcyte	0.00%	-2.25%	-7.17%	+11.55%	+83.09%
PRAX Praxis Precision Medicines	0.00%	-10.65%	-20.46%	-1.46%	+608.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$67.74 -1.5%	$76.51	$47.22 ▼ $88.31	$8.43B	0.36	2.13 million shs	1.01 million shs
DAWN Day One Biopharmaceuticals	$21.53	$19.41	$5.64 ▼ $21.53	$2.22B	-1.74	1.52 million shs	2.99 million shs
PCVX Vaxcyte	$59.09 +1.7%	$58.47	$31.51 ▼ $65.00	$8.79B	1.22	1.38 million shs	788,789 shs
PRAX Praxis Precision Medicines	$298.63 -0.1%	$339.20	$41.78 ▼ $392.70	$8.34B	2.76	458,070 shs	436,678 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-6.76%	-10.49%	-13.12%	+41.35%
DAWN Day One Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+216.15%
PCVX Vaxcyte	0.00%	-2.25%	-7.17%	+11.55%	+83.09%
PRAX Praxis Precision Medicines	0.00%	-10.65%	-20.46%	-1.46%	+608.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.85	Moderate Buy	$103.37	52.60% Upside
DAWN Day One Biopharmaceuticals	2.00	Hold	$23.29	8.15% Upside
PCVX Vaxcyte	2.57	Moderate Buy	$98.00	65.85% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$612.42	105.08% Upside

Current Analyst Ratings Breakdown

Latest DAWN, PRAX, PCVX, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	CYTK Cytokinetics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight ➝ Buy
8/31/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/14/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$95.00 ➝ $110.00
8/13/2026	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$97.00 ➝ $103.00
8/12/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/10/2026	CYTK Cytokinetics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$106.00 ➝ $112.00

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$67.67M	124.56	N/A	N/A	($5.39) per share	-12.57
DAWN Day One Biopharmaceuticals	$158.18M	14.06	N/A	N/A	$4.30 per share	5.01
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	$34.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
DAWN Day One Biopharmaceuticals	-$107.32M	-$1.03	N/A	2,153.00	N/A	-67.85%	-23.43%	-20.69%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)

Latest DAWN, PRAX, PCVX, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	6.66	6.66
DAWN Day One Biopharmaceuticals	N/A	8.02	7.91
PCVX Vaxcyte	N/A	5.72	5.72
PRAX Praxis Precision Medicines	N/A	15.73	15.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
DAWN Day One Biopharmaceuticals	87.95%
PCVX Vaxcyte	96.78%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
DAWN Day One Biopharmaceuticals	6.20%
PCVX Vaxcyte	3.30%
PRAX Praxis Precision Medicines	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
DAWN Day One Biopharmaceuticals	60	103.33 million	96.93 million	Optionable
PCVX Vaxcyte	507	148.81 million	143.89 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable

DAWN, PRAX, PCVX, and CYTK Headlines

Recent News About These Companies

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts

September 21 at 2:28 AM | americanbankingnews.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 21 at 2:28 AM | marketbeat.com

Praxis Precision Medicines Inc (PRAX)

September 19 at 7:53 PM | in.investing.com

Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

September 12, 2026 | seekingalpha.com

8,060 Shares in Praxis Precision Medicines, Inc. $PRAX Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

September 11, 2026 | marketbeat.com

California State Teachers Retirement System Sells 874 Shares of Praxis Precision Medicines, Inc. $PRAX

September 11, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Bought Rep. Gilbert Ray Cisneros, Jr.

September 8, 2026 | marketbeat.com

Readystate Asset Management LP Takes $3.53 Million Position in Praxis Precision Medicines, Inc. $PRAX

September 7, 2026 | marketbeat.com

Seven Fleet Capital Management LP Acquires Shares of 7,540 Praxis Precision Medicines, Inc. $PRAX

September 5, 2026 | marketbeat.com

PRAX stock reacts to new Nasdaq inducement grants

September 4, 2026 | ad-hoc-news.deA

Wellington Management Group LLP Sells 48,483 Shares of Praxis Precision Medicines, Inc. $PRAX

September 4, 2026 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

Praxis Precision Medicines, Inc. $PRAX is Velan Capital Investment Management LP's Largest Position

September 2, 2026 | marketbeat.com

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

August 31, 2026 | barrons.com

Bank of New York Mellon Corp Makes New $28.58 Million Investment in Praxis Precision Medicines, Inc. $PRAX

August 30, 2026 | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Buy" from Brokerages

August 27, 2026 | marketbeat.com

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

August 17, 2026 | finance.yahoo.com

RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

August 11, 2026 | theglobeandmail.com

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

August 11, 2026 | zacks.com

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

August 8, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Charles River Labs (CRL) and Senseonics Holdings (SENS)

August 8, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, PRAX, PCVX, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

$67.74 -1.04 (-1.51%)

As of 03:57 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals NASDAQ:DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Vaxcyte NASDAQ:PCVX

$59.09 +0.96 (+1.65%)

As of 03:57 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Praxis Precision Medicines NASDAQ:PRAX

$298.63 -0.32 (-0.11%)

As of 03:58 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DAWN, PRAX, PCVX, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DAWN, PRAX, PCVX, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DAWN, PRAX, PCVX, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, PRAX, PCVX, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

Day One Biopharmaceuticals NASDAQ:DAWN

Vaxcyte NASDAQ:PCVX

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DAWN, PRAX, PCVX, and CYTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DAWN, PRAX, PCVX, and CYTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DAWN, PRAX, PCVX, and CYTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, PRAX, PCVX, and CYTK Company Descriptions

Cytokinetics NASDAQ:CYTK

Day One Biopharmaceuticals NASDAQ:DAWN

Vaxcyte NASDAQ:PCVX

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools